Central regulation of ejaculation and the therapeutic role of serotonergic agents in premature ejaculation

Current Opinion in Investigational Drugs

Volumn 10, Issue 7, 2009, Pages 681-690

  Patel, Kush ^a   Hellstrom, Wayne J G ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 HT; CNS; Dapoxetine; Premature ejaculation; Serotonin; SSRI

Indexed keywords

5 CYANO 3 [2 (DIMETHYLAMINOMETHYL)CYCLOPROPYL]INDOLE; CITALOPRAM; CLOMIPRAMINE; DAPOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDRO 2 ISOQUINOLINYL)ETHYL]CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE; PAROXETINE; PINDOLOL; ROBALZOTAN; SEROTONIN; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SILDENAFIL; SULPIRIDE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

ABDOMINAL PAIN; AGITATION; AKATHISIA; ANOREXIA; ANORGASMIA; ANXIETY DISORDER; ASTHENIA; BACKACHE; BLOOD PRESSURE; BRADYKINESIA; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSTONIA; EJACULATION; EJACULATION DISORDER; ERECTILE DYSFUNCTION; EUROPE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FLU LIKE SYNDROME; GAIT DISORDER; HEADACHE; HUMAN; HYPERHIDROSIS; INSOMNIA; LATENT PERIOD; LETHARGY; LIBIDO DISORDER; LOOSE FECES; NAUSEA; NONHUMAN; PENIS ERECTION; PREMATURE EJACULATION; QUALITY OF LIFE; REVIEW; RHINOPHARYNGITIS; RIGIDITY; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SYNCOPE; TREATMENT RESPONSE; TREMOR; VOMITING; WITHDRAWAL SYNDROME; XEROSTOMIA; YAWNING;

ANTIDEPRESSIVE AGENTS; BENZYLAMINES; BRAIN; CLINICAL TRIALS AS TOPIC; EJACULATION; HUMANS; MALE; NAPHTHALENES; NEUROTRANSMITTER AGENTS; SEROTONIN AGENTS; SEROTONIN UPTAKE INHIBITORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 68149129504     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Laumann EO, Paik A, Rosen RC: Sexual dysfunction in the United States: Prevalence and predictors. J Am Med Assoc. (1999) 281(6):537-544.
2. Porst H, Montorsi F, Rosen RC, Gaynor L, Grupe S, Alexander J: The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: Prevalence, comorbidities, and professional help-seeking. Eur Urol. (2007) 51(3):816-824.
3. Byers ES, Grenier G: Premature or rapid ejaculation: Heterosexual couples' perceptions of men's ejaculatory behavior. Arch Sex Behav. (2003) 32(3):261-270.
4. Patrick DL, Althof SE, Pryor JL, Rosen R, Rowland DL, Ho KF, McNulty P, Rothman M, Jamieson C: Premature ejaculation: An observational study of men and their partners. J Sex Med. (2005) 2(3):358-367.
5. Giuliano F, Patrick DL, Porst H, La Pera G, Kokoszka A, Merchant S, Rothman M, Gagnon DD, Polverejan E: Premature ejaculation: Results from a five-country European observational study. Eur Urol. (2008) 53(5):1048-1057.
6. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth edition, Text revision. American Psychiatric Association, Washington, DC, USA (2000).
7. Shabsigh R, Rowland D: The Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision as an appropriate diagnostic for premature ejaculation. J Sex Med. (2007) 4(5):1468-1478.
8. McMahon CG, Althof S, Waldinger MD, Porst H, Dean J, Sharlip I, Adaikan PG, Becher E, Broderick GA, Buvat J, Dabees K et al:. An evidence-based definition of lifelong premature ejaculation: Report of the International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. BJU Int. (2008) 102(3):338-350. Details the new ISSM criteria for the diagnosis of PE, including the evidence-based approach used in the development of these criteria.
9. Xin ZC, Chung WS, Choi YD, Seong DH, Choi YJ, Choi HK: Penile sensitivity in patients with primary premature ejaculation. J Urol. (1996) 156(3):979-981.
10. Xin ZC, Choi YD, Rha KH, Choi HK: Somatosensory evoked potentials in patients with primary premature ejaculation. J Urol. (1997) 158(2):451-455.
11. Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B: Effect of SSRI antidepressants on ejaculation: A double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol. (1998) 18(4):274-281.
12. Waldinger MD, Zwinderman AH, Olivier B: Antidepressants and ejaculation: A double-blind, randomized, placebo-controlled, fixed-dose study with paroxetine, sertraline, and nefazodone. J Clin Psychopharmacol. (2001) 21(3):293-297.
13. Waldinger MD, Zwinderman AH, Olivier B: SSRIs and ejaculation: A double-blind, randomized, fixed-dose study with paroxetine and citalopram. J Clin Psychopharmacol. (2001) 21(6):556-560.
14. Waldinger MD, Zwinderman AH, Olivier B: Antidepressants and ejaculation: A double-blind, randomized, fixed-dose study with mirtazapine and paroxetine. J Clin Psychopharmacol. (2003) 23(5):467-470.
15. Montejo-González AL, Llorca G, Izquierdo JA, Ledesma A, Bousoño M, Calcedo A, Carrasco JL, Ciudad J, Daniel E, De la Gandara J, Derecho J et al:. SSRI-induced sexual dysfunction: Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther. (1997) 23(3):176-194.
16. Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R, Miloslavsky M, Kell S: Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation: Integrated analysis of two randomized, double-blind, placebo-controlled trials. Lancet. (2006) 368(9539):929-937.Presents the integrated analysis of data from two randomized, controlled clinical trials in the US of dapoxetine on-demand for the treatment of PE.
17. Kaufman JM, Rosen RC, Mudumbi RV, Tesfaye F, Hashmonay R, Rivas D: Treatment benefit of dapoxetine for premature ejaculation: Results from a placebo-controlled phase III trial. BJU Int. (2009) 103(5):651-658.One of five randomized, controlled clinical trials that support the use of dapoxetine on-demand for the treatment of PE. This trial, conducted in the US and Canada, highlighted improvement in patient-reported outcomes and included a randomized withdrawal period to assess the potential for discontinuation syndrome.
18. Buvat J, Tesfaye F, Rothman M, Rivas D, Giuliano F: Dapoxetine for the treatment of premature ejaculation: Results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. Eur Urol. (2009) 55(4):957-968.An international clinical trial of dapoxetine for the treatment of PE that demonstrates the efficacy and safety of dapoxetine (30 and 60 mg) on-demand, compared with placebo. To date, this is the most comprehensive and the longest duration trial conducted in men with PE.
19. McMahon C, Park NC, Zhao Y, Rothman M, Rivas D: Treatment of premature ejaculation (PE) in the Asia-Pacific region: Results from a phase III double-blind, parallel-group study of dapoxetine. Biennial Meeting of the Asia Pacific Society for Sexual Medicine, Jeju, Korea. (2007) 11:Abs OS-05-06.
20. Giuliano F: 5-Hydroxytryptamine in premature ejaculation: Opportunities for therapeutic intervention. Trends Neurosci. (2006) 30(2):79-84.
21. Waldinger MD: The neurobiological approach to premature ejaculation. J Urol. (2002) 168(6):2359-2367.
22. Coolen LM, Allard J, Truitt WA, McKenna KE: Central regulation of ejaculation. Physiol Behav. (2004) 83(2):203-215.
23. Giuliano F, Clement P: Physiology of ejaculation: Emphasis on serotonergic control. Eur Urol. (2005) 48(3):408-417. Highlights the role of 5-HT in PE and establishes the physiology underlying current centrally acting treatment options, mainly SSRIs.
24. Holstege G, Georgiadis JR, Paans AM, Meiners LC, van der Graaf FH, Reinders AA: Brain activation during human male ejaculation. J Neurosci. (2003) 23(27):9185-9193.
25. Baum MJ, Everitt BJ: Increased expression of c-fos in the medial preoptic area after mating in male rats: Role of afferent inputs from the medial amygdala and midbrain central tegmental field. Neuroscience. (1992) 50(3):627-646.
26. Coolen LM, Peters HJ, Veening JG: Fos immunoreactivity in the rat brain following consummatory elements of sexual behavior: A sex comparison. Brain Res. (1996) 738(1):67-82.
27. Hamson DK, Watson NV: Regional brainstem expression of Fos associated with sexual behavior in male rats. Brain Res. (2004) 1006(2):233-240.
28. Johnson RD, Hubscher CH: Brainstem microstimulation differentially inhibits pudendal motoneuron reflex inputs. Neuroreport. (1998) 9(2):341-345.
29. Hull EM, Du J, Lorrain DS, Matuszewich L: Extracellular dopamine in the medial preoptic area: Implications for sexual motivation and hormonal control of copulation. J Neurosci. (1995) 15(11):7465-7471.
30. Marson L, McKenna KE: A role for 5-hydroxytryptamine in descending inhibition of spinal sexual reflexes. Exp Brain Res. (1992) 88(2):313-320.
31. Olivier B, van Oorschot R, Waldinger MD: Serotonin, serotonergic receptors, selective serotonin reuptake inhibitors and sexual behaviour. Int Clin Psychopharmacol. (1998) 13(Suppl 6):S9-S14.
32. Waldinger MD, Berendsen HH, Blok BF, Olivier B, Holstege G: Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation: The involvement of the serotonergic system. Behav Brain Res. (1998) 92(2):111-118.
33. Ahlenius S, Larsson K: Specific involvement of central 5-HT 1A receptors in the mediation of male rat ejaculatory behavior. Neurochem Res. (1997) 22(8):1065-1070.
34. Hillegaart V, Ahlenius S: Facilitation and inhibition of male rat ejaculatory behaviour by the respective 5-HT 1A and 5-HT 1B receptor agonists 8-OH-DPAT and anpirtoline, as evidenced by use of the corresponding new and selective receptor antagonists NAD-299 and NAS-181. Br J Pharmacol. (1998) 125(8):1733-1743.
35. Peeters M, Giuliano F: Central neurophysiology and dopaminergic control of ejaculation. Neurosci Biobehav Rev. (2008) 32(3):438-453.
36. 3 receptor antagonist, in the rat. J Sex Med. (2009) 6(4):980-988.
37. Damsa C, Bumb A, Bianchi-Demicheli F, Vidailhet P, Sterck R, Andreoli A, Beyenburg S: "Dopamine-dependent" side effects of selective serotonin reuptake inhibitors: A clinical review. J Clin Psychiatry. (2004) 65(8):1064-1068.
38. Filippi S, Vignozzi L, Vannelli GB, Ledda F, Forti G, Maggi M: Role of oxytocin in the ejaculatory process. J Endocrinol Invest. (2003) 26(3 Suppl):82-86.
39. Bitran D, Hull EM: Pharmacological analysis of male rat sexual behavior. Neurosci Biobehav Rev. (1987) 11(4):365-389.
40. Clément P, Peeters M, Bernabé J, Denys P, Alexandre L, Giuliano F: Brain oxytocin receptors mediate ejaculation elicited by 7-hydroxy-2-(di-/V-propylamino) tetralin (7-OH-DPAT) in anaesthetized rats. Br J Pharmacol. (2008) 154(5):1150-1159.
41. Waldinger MD, Olivier B: Utility of selective serotonin reuptake inhibitors in premature ejaculation. Curr Opin Investig Drugs. (2004) 5(7):743-747.
42. Waldinger MD: Relevance of an evidence-based ejaculation time cutoff point for neurobiological research of premature ejaculation. J Comp Neurol. (2005) 493(1):46-50.
43. McMahon CG: Clinical trial methodology in premature ejaculation observational, interventional, and treatment preference studies-part II-study design, outcome measures, data analysis, and reporting. J Sex Med. (2008) 5(8):1817-1833.
44. Novaretti JPT, Pompeo ACL, Arap S: Selective serotonin re-uptake inhibitor in the treatment of premature ejaculation. Braz J Urol. (2002) 28(2):116-122.
45. Buvat J, Giuliano F, Tesfaye F, Rothman M, Rivas D: Efficacy and safety of dapoxetine for premature ejaculation (PE): Results from a placebo-controlled, double-blind, randomized, parallel- group study in 22 countries. Urology. (2007) 70(3):Abs POD-05.05.
46. Safarinejad MR: Safety and efficacy of venlafaxine in the treatment of premature ejaculation: A double-blind, placebo- controlled, fixed-dose, randomised study. Andrologia. (2008) 40(1):49-55.
47. Safarinejad MR: Safety and efficacy of escitalopram in the treatment of premature ejaculation: A double-blind, placebo- controlled, fixed-dose, randomized study. J Clin Psychopharmacol. (2007) 27(5):444- 450.
48. Althof S, Rosen R, Symonds T, Mundayat R, May K, Abraham L:Development and validation of a new questionnaire to assess sexual satisfaction, control, and distress associated with premature ejaculation. J Sex Med. (2006) 3(3):465-475.
49. Hartmann U: The "PEQUEST": A multidimensional instrument for the assessment of premature ejaculation. Int J Impot Res. (1996) 8:Abs A81.
50. Yuan YM, Xin ZC, Jiang H, Guo YJ, Liu WJ, Tian L, Zhu JC: Sexual function of premature ejaculation patients assayed with Chinese Index of Premature Ejaculation. Asian J Androl. (2004) 6(2):121-126.
51. Arafa M, Shamloul R: Development and evaluation of the Arabic Index of Premature Ejaculation (AIPE). J Sex Med. (2007) 4(6):1750- 1756.
52. Rosen RC, McMahon CG, Niederberger C, Broderick GA, Jamieson C, Gagnon DD: Correlates to the clinical diagnosis of premature ejaculation: Results from a large observational study of men and their partners. J Urol. (2007) 177(3):1059-1064.
53. Patrick DL, Giuliano F, Ho KF, Gagnon DD, McNulty P, Rothman M: The Premature Ejaculation Profile: Validation of self-reported outcome measures for research and practice. BJU Int. (2009) 103(3):358-364.
54. Rosen RC, Cappelleri JC, Gendrano N: The International Index of Erectile Function (IIEF): A state-of-the-science review. Int J Impot Res. (2002) 14(4):226-244..
55. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A: The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology. (1997) 49(6):822-830.
56. Abdel-Hamid IA, El Naggar EA, El Gilany A-H: Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation. Int J Impot Res. (2001) 13(1):41-45.
57. Waldinger MD, Zwindermann AH, Schweitzer DH, Olivier B: Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: A systematic review and meta-analysis. Int J Impot Res. (2004) 16(4):369-381.
58. Wang WF, Chang L, Minhas S, Ralph DJ: Selective serotonin reuptake inhibitors in the treatment of premature ejaculation. Chin Med J (Engl). (2007) 120(11):1000-1006.
59. Akgül T, Karakan T, Ayyildiz A, Germiyanoglu C: Comparison of sertraline and citalopram for treatment of premature ejaculation. Urol J. (2008) 5(1):41-45.
60. Safarinejad MR, Hosseini SY: Safety and efficacy of citalopram in the treatment of premature ejaculation: A double-blind placebo-controlled, fixed dose, randomized study. Int J Impot Res. (2006) 18(2):164-169.
61. Athanasios Z, Polyanthi P, George K: The efficacy of duloxetine in the treatment of premature ejaculation. Int Urol Nephrol. (2007) 39(1):115-118.
62. Maj J, Rogoz Z: Pharmacological effects of venlafaxine, a new antidepressant, given repeatedly, on the a 11 -adrenergic, dopamine and serotonin systems. J Neural Transm. (1999) 106(2):197-211.
63. ZOLOFT® (sertraline hydrochloride): Tablets and oral concentrate. Pfizer Ltd, New York, NY, USA (2005). www.pfizer.com/ filesfproductsfuspi-zoloft.pdf
64. PAXIL® (paroxetine hydrochloride): Tablets and oral suspension. GlaxoSmithKline plc, Research Triangle Park, NC, USA (2007). us.gsk.com/products/assets/us-paxil.pdf
65. Hiemke C, Hartter S: Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. (2000) 85(1):11-28.
66. McMahon CG: Treatment of premature ejaculation with sertraline hydrochloride: A single-blind placebo controlled crossover study. J Urol. (1998) 159(6):1935-1938.
67. McMahon CG, Touma K: Treatment of premature ejaculation with paroxetine hydrochloride. Int J Impot Res. (1999) 11(5):241-245.
68. Montague DK, Jarow J, Broderick GA, Dmochowski RR, Heaton JP, Lue TF, Nehra A, Sharlip ID: AUA guideline on the pharmacologic management of premature ejaculation. J Urol. (2004) 172(1):290-294.
69. Waldinger MD, Zwinderman AH, Olivier B: On-demand treatment of premature ejaculation with clomipramine and paroxetine: A randomized, double-blind fixed-dose study with stopwatch assessment. Eur Urol. (2004) 46(4):510-516.
70. Atmaca M, Kuloglu M, Tezcan E, Semercioz A: The efficacy of citalopram in the treatment of premature ejaculation: A placebo-controlled study. Int J Impot Res. (2002) 14(6):502-505.
71. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F: Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients. J Clin Psychiatry. (2001) 62(Suppl 3):10-21.
72. Kim SC, Seo KK: Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: A double- blind, placebo controlled study. J Urol. (1998) 159(2):425-427.
73. Black K, Shea C, Dursun S, Kutcher S: Selective serotonin reuptake inhibitor discontinuation syndrome: Proposed diagnostic criteria. J Psychiatry Neurosci. (2000) 25(3):255-261.
74. Haddad P: The SSRI discontinuation syndrome. J Psychopharmacol. (1998) 12(3):305-313.
75. Tamam L, Ozpoyraz N: Selective serotonin reuptake inhibitor discontinuation syndrome: A review. Adv Ther. (2002) 19(1):17-26.
76. Modi NB, Dresser MJ, Simon M, Lin D, Desai D, Gupta S: Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol. (2006) 46(3):301-309.
77. Hellstrom WJG: Emerging treatments for premature ejaculation: Focus on dapoxetine. Neuropsychiatr Dis Treat. (2009) 5:37-46. Presents a thorough review of dapoxetine and the phase III clinical trials of this compound.
78. Park NC, McMahon C, Tesfaye F, Zhao Y, Rothman M, Rivas D: Safety and tolerability of dapoxetine for the treatment of premature ejaculation in an Asia-Pacific population. Biennial Meeting of the Asia Pacific Society for Sexual Medicine, Jeju, Korea. (2007) 11:Abs OS-05-07.
79. McMahon CG, Althof SE, Kaufman JM, Buvat J, Aquilina J, Rivas D, Tesfaye F, Rothman M: Efficacy and safety of dapoxetine for premature ejaculation: Integrated analysis of 5 phase III trials. J Sex Med. (2009) 6:Abs PD-068.
80. Moore DP, Jefferson JW (Eds): Selective serotonin reuptake inhibitors. In: Handbook of Medical Psychiatry. 2nd Edition. Mosby Inc, Philadelphia, PA, USA (2004):453-455.
81. Casey R, Tesfaye F, Mudumbi R, Rothman M, Rivas D: Effects of dapoxetine (DPX) for the treatment of premature ejaculation (PE) on the erectile function and scales of mood and affect. Eur Urol Suppl. (2008) 7(3):Abs 463.
82. Giuliano F, Levine SB, Buvat J, Rosen RC, Kaufman JM, Tesfaye F, Rothman M, Rivas D: Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): Results from 2 phase III trials. Eur Urol Suppl. (2008) 7:Abs 465.
83. Taber MT, Wright RN, Molski TF, Clarke WJ, Brassil PJ, Denhart DJ, Mattson RJ, Lodge NJ: Neurochemical, pharmacokinetic, and behavioral effects of the novel selective serotonin reuptake inhibitor BMS-505130. Pharmacol Biochem Behav. (2005) 80(3):521-528.
84. Looney C, Thor KB, Ricca D, Marson L: Differential effects of simultaneous or sequential administration of paroxetine and WAY-100,635 on ejaculatory behavior. Pharmacol Biochem Behav. (2005) 82(3):427-433.
85. Safarinejad MR: Once-daily high-dose pindolol for paroxetine- refractory premature ejaculation: A double-blind, placebo- controlled and randomized study. J Clin Psychopharmacol. (2008) 28(1):39-44.
86. Greco E, Polonio-Balbi P, Speranza JC: Levosulpiride: A new solution for premature ejaculation?Int J Impot Res. (2002) 14(4):308-309.
87. Safarinejad MR, Hosseini SY: Safety and efficacy of tramadol in the treatment of premature ejaculation: A double-blind, placebo- controlled, fixed-dose, randomized study. J Clin Psychopharmacol. (2006) 26(1):27-31.The first of two randomized, controlled clinical trials that established tramadol on-demand as a potential treatment option for PE and demonstrated significant increases in IELT compared with placebo.
88. Salem EA, Wilson SK, Bissada NK, Delk JR, Hellstrom WJ, Cleves MA: Tramadol HCl has promise in on-demand use to treat premature ejaculation. J Sex Med. (2008) 5(1):188-193.The second of two randomized, controlled clinical trials that establish tramadol as a potential treatment option for PE, with significant increases in IELT compared with placebo.
89. Hernandez-Lopez C, Martinez-Farnos L, Karhu D, Perez-Campos T, Rovira S, Encina G: Comparative bioavailability between two tramadol once-daily oral formulations. Methods Find Exp Clin Pharmacol. (2006) 28(6):373-378.
90. Barnes T, Eardley I: Premature ejaculation: The scope of the problem. J Sex Marital Ther. (2007) 33(2):151-170.
91. Giuliano F, Hellstrom WJ: The pharmacological treatment of premature ejaculation. BJU Int. (2008) 102(6):668-675.
92. McMahon CG, McMahon CN, Leow LJ, Winestock CG: Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: A systematic review. BJU Int. (2006) 98(2):259-272.